# ATEMPT 2.0 (NCT04893109)

> ATEMPT 2.0: Adjuvant T-DM1 vs TH

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04893109
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; HER2-positive Breast Cancer
- Interventions: trastuzumab-emtansine; Trastuzumab SC; Paclitaxel
- Enrollment: 500
- Primary outcome: Incidence of clinically relevant toxicities (CRT)
- Primary outcome: Disease Free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=atempt-2-0-nct04893109